The Relationship Between Autoimmune Disease and Disease-Modifying Antirheumatic Drugs on Wound Healing
| العنوان: | The Relationship Between Autoimmune Disease and Disease-Modifying Antirheumatic Drugs on Wound Healing |
|---|---|
| المؤلفون: | Kenneth L. Fan, Christopher E. Attinger, Karen K. Evans, Elizabeth G. Zolper, Jenna C. Bekeny, Helena B. Pasieka, Julianne Kiene, Ashley Rogers, Paige K. Dekker, Carol Deane Benedict, Suzanne Zhou, Kunal M Kirloskar |
| المصدر: | Advances in Wound Care. 11:650-656 |
| بيانات النشر: | Mary Ann Liebert Inc, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Autoimmune disease, Wound Healing, medicine.medical_specialty, integumentary system, business.industry, Anti rheumatic drugs, Disease, Strengthening the reporting of observational studies in epidemiology, Critical Care and Intensive Care Medicine, medicine.disease, Diabetic foot, Diabetic Foot, Autoimmune Diseases, Wound care, Antirheumatic Agents, Internal medicine, Cohort, Emergency Medicine, Humans, Medicine, Wound healing, business, Retrospective Studies |
| الوصف: | Objective To evaluate the role of disease-modifying anti-rheumatic drugs (DMARDs) on wound healing outcomes of patients with autoimmune disease at our tertiary wound care center. Approach Retrospective review of patients presenting to our wound care center between 2014 and 2018 with both chronic wounds and a history of inflammatory disease. Patient demographics, comorbid conditions, and progression to complete wound healing were compared between those taking DMARDs or not at the time of wound onset. The study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Results 58 patients with a total of 296 wounds were retrospectively reviewed. Patients were taking at least one DMARD at wound onset in 217 (73.3%) of these wounds. The average number of DMARDs at wound onset was 1.5 (SD 1.2). 210 wounds progressed to heal (70.9%) with a median time to healing of 229.5 days (IQR 71.0-490.0). Of the 210 wounds that healed, patients taking at least one DMARD had a significantly shorter time to healing relative to patients who were not on any DMARDs (median 190.5 vs 340.0 days, p=0.0156). Innovation Characterizing wound healing outcomes at a tertiary hospital with a dedicated wound care center and analyzing the role of DMARDs in wound healing progression. Conclusions Chronic wounds are notoriously challenging to treat in the setting of autoimmune disease. The median time to healing in the studied cohort was 229.5 days, which is alarming when compared to patients with non-infected diabetic foot ulcers, who take a median time to heal of 30.8 days at our institution.10. |
| تدمد: | 2162-1934 2162-1918 |
| DOI: | 10.1089/wound.2021.0150 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2479ad1abc91d7d11ac897b255f06030 https://doi.org/10.1089/wound.2021.0150 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2479ad1abc91d7d11ac897b255f06030 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21621934 21621918 |
|---|---|
| DOI: | 10.1089/wound.2021.0150 |